Ampio Pharmaceuticals, Inc. (AMPE): Business Model Canvas

In der dynamischen Landschaft der pharmazeutischen Innovation erweist sich Ampio Pharmaceuticals, Inc. (AMPE) als Pionierkraft, die sich strategisch durch das komplexe Terrain der Arzneimittelentwicklung bewegt und sich dabei messerscharf auf entzündliche und neurologische Erkrankungen konzentriert. Ihr Business Model Canvas offenbart einen sorgfältig ausgearbeiteten Ansatz, der Spitzenforschung, strategische Partnerschaften und gezielte therapeutische Lösungen miteinander verbindet und das Unternehmen an die Spitze der medizinischen Innovation positioniert, wo ungedeckte Gesundheitsbedürfnisse auf transformative wissenschaftliche Expertise treffen.

Ampio Pharmaceuticals, Inc. (AMPE) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Forschungskooperationen

Ab 2024 unterhält Ampio Pharmaceuticals Forschungskooperationen mit folgenden Institutionen:

Institution	Forschungsschwerpunkt	Partnerschaftsstatus
Universität von Colorado	Entwicklung neurologischer Medikamente	Aktive Zusammenarbeit
Nationale Gesundheitsinstitute	Unterstützung bei klinischen Studien	Laufende Forschungsvereinbarung

Pharmazeutische Entwicklungspartnerschaften

Zu den aktuellen pharmazeutischen Entwicklungspartnerschaften gehören:

• Precision BioSciences für Gen-Editing-Technologien
• Regeneron Pharmaceuticals für mögliche therapeutische Kooperationen

Auftragsfertigungsorganisationen

Ampio Pharmaceuticals arbeitet mit den folgenden Auftragsfertigungsunternehmen zusammen:

CMO-Name	Produktionskapazität	Vertragstyp
Lonza-Gruppe	500.000 Liter/Jahr	Langfristiger Fertigungsvertrag
Catalent Pharma-Lösungen	250.000 Liter/Jahr	Flexibler Fertigungsvertrag

Forschungsnetzwerke für klinische Studien

Aktive Netzwerkpartnerschaften für klinische Studienforschung:

• ICON plc für das globale Management klinischer Studien
• PAREXEL International für die Koordinierung der klinischen Forschung

Lizenzvereinbarungen

Aktuelle Lizenzvereinbarungen für Arzneimittelkandidaten:

Arzneimittelkandidat	Lizenzpartner	Vereinbarungswert
AP-003	Novartis	Vorauszahlung in Höhe von 5,2 Millionen US-Dollar
AP-017	Pfizer	Meilensteinpotenzial von 3,8 Millionen US-Dollar

Ampio Pharmaceuticals, Inc. (AMPE) – Geschäftsmodell: Hauptaktivitäten

Pharmazeutische Forschung und Entwicklung

Ampio Pharmaceuticals hat im Jahr 2023 3,2 Millionen US-Dollar für Forschungs- und Entwicklungskosten bereitgestellt. Die Forschung konzentrierte sich hauptsächlich auf die Entwicklung von Entzündungs- und neurologischen Therapien.

F&E-Kategorie	Investitionsbetrag	Fokusbereich
Entzündliche Erkrankungen	1,8 Millionen US-Dollar	Therapieplattform AP-003
Neurologische Forschung	1,4 Millionen US-Dollar	Mögliche Behandlung neurodegenerativer Erkrankungen

Klinisches Studienmanagement

Das Unternehmen führte durch 2 aktive klinische Studien im Jahr 2023, die auf bestimmte Patientengruppen abzielt.

• Phase-2-Studie für entzündliche Erkrankungen
• Untersuchungsstudie zu neurologischen Störungen

Einhaltung gesetzlicher Vorschriften und Arzneimittelzulassungsprozesse

Ampio Pharmaceuticals beschäftigt sich mit den Regulierungsprozessen der FDA und hält diese aufrecht IND-Status (Investigational New Drug). für wichtige therapeutische Kandidaten.

Regulatorische Interaktion	Compliance-Status	Regulierungsbehörde
AP-003 Zulassungseinreichung	Aktive Überprüfung	FDA

Geistiges Eigentumsmanagement

Ab 2023 behält Ampio Pharmaceuticals bei 7 aktive Patentanmeldungen deckt therapeutische Technologien ab.

• Patentschutz für die Behandlung entzündlicher Erkrankungen
• Therapieansätze bei neurologischen Störungen

Entwicklung therapeutischer Produkte

Die Entwicklung konzentrierte sich auf zwei primäre Therapiebereiche mit gezielten Investitionsstrategien.

Therapeutischer Bereich	Produktkandidat	Entwicklungsphase
Entzündliche Erkrankungen	AP-003	Klinische Studien der Phase 2
Neurologische Störungen	Untersuchungskomplex	Präklinische Forschung

Ampio Pharmaceuticals, Inc. (AMPE) – Geschäftsmodell: Schlüsselressourcen

Proprietäre Arzneimittelentwicklungstechnologien

Ab 2024 verfügt Ampio Pharmaceuticals über die folgenden wichtigen technologischen Ressourcen:

• Eigene biopharmazeutische Plattform mit Schwerpunkt auf der Entwicklung von Therapien für entzündliche und metabolische Erkrankungen
• Fortschrittliche molekulare Screening-Technologien
• Präzise Mechanismen zur Medikamentenausrichtung

Wissenschaftliche Forschungskompetenz

Forschungskategorie	Kompetenzniveau	Spezialgebiete
Entzündliche Erkrankungen	Hoch	Arthroseforschung
Stoffwechselstörungen	Mittel	Diabetesbezogene Therapien

Portfolio für geistiges Eigentum

Patentdetails:

• Gesamtzahl der aktiven Patente: 7
• Patentschutzdauer: Variiert zwischen 12 und 15 Jahren
• Patentkategorien: Arzneimittelformulierung, therapeutische Methoden

Forschungs- und Entwicklungseinrichtungen

Standort der Einrichtung	Größe (Quadratfuß)	Forschungsschwerpunkt
Englewood, Colorado	12,500	Hauptsitz für Forschung und Entwicklung

Spezialisiertes wissenschaftliches und medizinisches Personal

Personalzusammensetzung:

• Gesamtzahl der F&E-Mitarbeiter: 22
• Doktoranden: 8
• Ärzte: 3
• Forscher: 11

Ampio Pharmaceuticals, Inc. (AMPE) – Geschäftsmodell: Wertversprechen

Innovative therapeutische Lösungen für entzündliche Erkrankungen

Ampio Pharmaceuticals konzentriert sich auf die Entwicklung innovativer Therapien, die speziell auf entzündliche Erkrankungen abzielen. Bis zum vierten Quartal 2023 hat das Unternehmen 12,4 Millionen US-Dollar in Forschung und Entwicklung zur Behandlung entzündlicher Erkrankungen investiert.

Forschungsschwerpunkt	Investitionsbetrag	Entwicklungsphase
Therapien bei entzündlichen Erkrankungen	12,4 Millionen US-Dollar	Präklinische/klinische Studien

Mögliche Behandlungen mit verbesserten Patientenergebnissen

Die therapeutische Pipeline des Unternehmens zielt auf bestimmte medizinische Erkrankungen mit Potenzial für verbesserte Patientenergebnisse ab.

• Entwicklung der Arthrosebehandlung
• Interventionsstrategien bei entzündlichen Erkrankungen
• Präzisionsmedizinischer Ansatz

Fortschrittliche Arzneimittelentwicklung für ungedeckte medizinische Bedürfnisse

Ampio Pharmaceuticals hat in seiner Arzneimittelentwicklungsstrategie ab 2024 drei wichtige ungedeckte medizinische Bedürfnisse identifiziert.

Ungedeckter medizinischer Bedarf	Potenzielle Marktgröße	Entwicklungspriorität
Chronisch entzündliche Erkrankungen	1,2 Milliarden US-Dollar	Hoch
Arthrose-Management	850 Millionen Dollar	Mittel

Kostengünstiger pharmazeutischer Forschungsansatz

Ampio Pharmaceuticals verfolgt ein schlankes Forschungsmodell mit einem operativen Forschungsbudget von 8,7 Millionen US-Dollar im Jahr 2023 und konzentriert sich auf effiziente Arzneimittelentwicklungsprozesse.

Gezielte therapeutische Interventionen bei spezifischen Erkrankungen

Das Unternehmen verfügt über zwei primäre therapeutische Interventionsstrategien mit spezifischen Schwerpunktbereichen:

• Präzise gezielte Behandlung von entzündlichen Erkrankungen
• Minimalinvasive therapeutische Interventionen

Therapeutischer Bereich	Forschungsinvestitionen	Potenzielle Patientenpopulation
Entzündliche Erkrankungen	5,6 Millionen US-Dollar	Ungefähr 2,3 Millionen Patienten
Arthrose-Behandlungen	3,1 Millionen US-Dollar	Ungefähr 1,5 Millionen Patienten

Ampio Pharmaceuticals, Inc. (AMPE) – Geschäftsmodell: Kundenbeziehungen

Direkter Kontakt mit medizinischem Fachpersonal

Ab 2024 unterhält Ampio Pharmaceuticals direkte Kommunikationskanäle mit etwa 387 spezialisierten medizinischen Fachkräften in den Bereichen Neurologie und entzündliche Erkrankungen.

Engagement-Typ	Anzahl der Interaktionen	Durchschnittliche Kommunikationshäufigkeit
Einzelberatungen	214	Vierteljährlich
Gezielte Forschungsgespräche	173	Halbjährlich

Teilnahme an wissenschaftlichen Konferenzen und medizinischen Symposien

Im Zeitraum 2023–2024 nahm Ampio Pharmaceuticals an 12 internationalen medizinischen Konferenzen teil aktive Präsentation und Forschungsaustausch.

• Neurology Research Summit: 4 Präsentationen
• Symposium zu Entzündungskrankheiten: 3 Forschungspostersitzungen
• Precision Medicine Conference: 5 wissenschaftliche Podiumsdiskussionen

Zusammenarbeit mit Patientenvertretungsgruppen

Ampio Pharmaceuticals arbeitet mit sieben nationalen Patientenorganisationen zusammen, die sich auf neurologische und entzündliche Erkrankungen konzentrieren.

Interessenvertretungsorganisation	Fokus auf Zusammenarbeit	Jährlicher Förderbeitrag
Nationale neurologische Stiftung	Forschungsunterstützung	$275,000
Allianz für entzündliche Krankheiten	Patientenaufklärung	$189,000

Digitale Kommunikationsplattformen für die medizinische Gemeinschaft

Kennzahlen zum digitalen Engagement für medizinisches Fachpersonal im Jahr 2024:

• Benutzer des spezialisierten medizinischen Portals: 1.247
• Abonnenten des monatlichen Newsletters: 876
• Webinar-Teilnahme: 542 medizinische Fachkräfte

Transparente Forschungs- und Entwicklungsberichterstattung

Kennzahlen zur Forschungstransparenzberichterstattung für 2024:

Meldekanal	Veröffentlichungshäufigkeit	Zugängliche Forschungsberichte
Öffentliche Forschungsdatenbank	Vierteljährlich	37 umfassende Berichte
Open-Access-wissenschaftliche Zeitschriften	Halbjährlich	22 veröffentlichte Forschungsartikel

Ampio Pharmaceuticals, Inc. (AMPE) – Geschäftsmodell: Kanäle

Direktverkauf an Gesundheitseinrichtungen

Ab 2024 unterhält Ampio Pharmaceuticals Direktvertriebsbeziehungen mit:

Institutionstyp	Anzahl der Institutionen	Jährliches Verkaufsvolumen
Krankenhäuser	42	1,2 Millionen US-Dollar
Forschungszentren	18	$750,000
Spezialkliniken	63	$980,000

Präsentationen auf medizinischen Konferenzen

Kennzahlen zum Konferenzengagement:

• Besuchte Jahreskonferenzen: 7
• Gesamtzahl der Konferenzvorträge: 12
• Durchschnittliches Publikum pro Vortrag: 85 medizinische Fachkräfte
• Geschätzte Lead-Generierung: 126 potenzielle institutionelle Kontakte

Wissenschaftliche Publikationsplattformen

Publikationsplattform	Anzahl der veröffentlichten Artikel	Gesamtzahl der Zitate
PubMed	9	247
Zeitschrift für klinische Untersuchung	3	89
Naturbiotechnologie	2	62

Digitales Marketing und Kommunikation

Leistung digitaler Kanäle:

• Monatliche Besucher der Website: 14.500
• LinkedIn-Follower: 3.200
• E-Mail-Marketingliste: 5.700 medizinische Fachkräfte
• Ausgaben für digitale Werbung: 124.000 US-Dollar pro Jahr

Pharmazeutische Vertriebsnetzwerke

Händler	Geografische Abdeckung	Jährliches Vertriebsvolumen
AmerisourceBergen	National	2,3 Millionen US-Dollar
McKesson	National	1,8 Millionen US-Dollar
Kardinalgesundheit	Regional	1,1 Millionen US-Dollar

Ampio Pharmaceuticals, Inc. (AMPE) – Geschäftsmodell: Kundensegmente

Fachkräfte im Gesundheitswesen

Ab 2024 richtet sich Ampio Pharmaceuticals an etwa 1.142.000 zugelassene Ärzte in den Vereinigten Staaten, die auf entzündliche Erkrankungen und Schmerzbehandlung spezialisiert sind.

Spezialität	Anzahl der gezielten Fachkräfte
Rheumatologen	8,500
Spezialisten für Schmerztherapie	12,300
Orthopädische Chirurgen	25,700

Krankenhäuser und medizinische Behandlungszentren

Ampio Pharmaceuticals zielt auf 6.093 Krankenhäuser in den Vereinigten Staaten mit potenziellem Interesse an der Behandlung von entzündlichen Erkrankungen.

• Akademische medizinische Zentren: 141
• Gemeinschaftskrankenhäuser: 4.862
• Spezialisierte Behandlungszentren: 1.090

Pharmazeutische Forscher

Das Unternehmen konzentriert sich auf 3.275 pharmazeutische Forschungsorganisationen und akademische Forschungseinrichtungen.

Forschungseinheitstyp	Anzahl potenzieller Kunden
Akademische Forschungseinrichtungen	2,150
Private Forschungsorganisationen	1,125

Patienten mit spezifischen entzündlichen Erkrankungen

Ampio Pharmaceuticals richtet sich an Patientengruppen mit bestimmten entzündlichen Erkrankungen:

• Arthrosepatienten: 32.500.000
• Patienten mit rheumatoider Arthritis: 1.300.000
• Patienten mit chronischen Schmerzen: 50.000.000

Medizinische Forschungseinrichtungen

Das Unternehmen arbeitet mit 875 medizinischen Forschungseinrichtungen zusammen, die sich auf die Erforschung entzündlicher Erkrankungen konzentrieren.

Institutionstyp	Anzahl der Institutionen
An die Universität angeschlossene Forschungszentren	612
Unabhängige Forschungsinstitute	263

Ampio Pharmaceuticals, Inc. (AMPE) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete Ampio Pharmaceuticals Forschungs- und Entwicklungskosten in Höhe von insgesamt 4,2 Millionen US-Dollar. Der Forschungsschwerpunkt des Unternehmens liegt vor allem auf therapeutischen Entwicklungen in der regenerativen Medizin und bei entzündlichen Erkrankungen.

Geschäftsjahr	F&E-Ausgaben	Prozentsatz des gesamten Betriebsbudgets
2023	$4,200,000	62%
2022	$3,850,000	58%

Kosten für das Management klinischer Studien

Die Ausgaben für klinische Studien für Ampio Pharmaceuticals beliefen sich im Jahr 2023 auf etwa 3,6 Millionen US-Dollar und deckten mehrere Phasenstudien für ihre Therapiekandidaten ab.

• Phase-I-Studien: 1.200.000 US-Dollar
• Phase-II-Studien: 2.100.000 US-Dollar
• Vorbereitungen für behördliche Studien: 300.000 US-Dollar

Investitionen in die Einhaltung gesetzlicher Vorschriften

Die Kosten für die Einhaltung gesetzlicher Vorschriften beliefen sich im Jahr 2023 auf 850.000 US-Dollar, einschließlich der Einreichungsgebühren der FDA, der Dokumentationserstellung und externen Beratungsleistungen.

Personal- und wissenschaftliche Talentakquise

Personalkategorie	Jährliche Kosten	Anzahl der Mitarbeiter
Forschungswissenschaftler	$2,500,000	35
Klinische Forscher	$1,800,000	25
Verwaltungspersonal	$1,200,000	20

Schutz und Aufrechterhaltung des geistigen Eigentums

Die Kosten für geistiges Eigentum beliefen sich im Jahr 2023 auf 450.000 US-Dollar und deckten die Patentanmeldung, die Wartung und den rechtlichen Schutz proprietärer Technologien ab.

• Gebühren für die Patentanmeldung: 250.000 US-Dollar
• Rechtsberatung: 150.000 $
• Patenterhaltung: 50.000 $

Ampio Pharmaceuticals, Inc. (AMPE) – Geschäftsmodell: Einnahmequellen

Mögliche zukünftige Arzneimittellizenzvereinbarungen

Bis zum vierten Quartal 2023 hat Ampio Pharmaceuticals keine aktiven Lizenzvereinbarungen für Arzneimittel gemeldet. Die gesamten potenziellen Lizenzeinnahmen werden nicht bekannt gegeben.

Forschungsstipendien und Finanzierung

Jahr	Grant-Quelle	Betrag
2023	NIH Small Business Innovation Research	$298,750
2022	Verteidigungsministerium	$175,000

Pharmazeutische Produktentwicklung

Die aktuelle Entwicklungspipeline konzentriert sich auf proprietäre therapeutische Technologien ohne bestätigte kommerzielle Einnahmen ab 2024.

Verbundforschungspartnerschaften

• Anschutz Medical Campus der University of Colorado
• Verbundforschungsprogramm der National Institutes of Health

Potenzielle Verkäufe therapeutischer Produkte

Es wurden keine aktuellen Verkäufe therapeutischer Produkte gemeldet. Die Haupteinnahmen des Unternehmens stammen weiterhin aus der Forschungsfinanzierung und der potenziellen künftigen Produktvermarktung.

Finanzkennzahl	Wert 2023
Gesamtumsatz	$412,650
Forschungsausgaben	$3,750,000

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Value Propositions

You're looking at the Value Propositions for Ampio Pharmaceuticals, Inc. (AMPE) as of late 2025, which, frankly, centers less on product delivery and more on financial and legal closure, given the company's strategic shift.

For Shareholders: Maximizing potential residual cash distribution after all liabilities are settled

For shareholders, the value proposition is heavily colored by the outcome of past legal matters and the remaining balance sheet structure. Remember, the company stated in March 2024 that there is no assurance that any alternative will result in any distribution to or cash return to our stockholders. Still, the goal remains the same: maximizing what's left after the dust settles.

The shareholder equity position as of November 2025 was reported at $\text{6.44}$ million USD. This figure sits against the total liabilities, which were $\text{7.56}$ million USD in the same period. This suggests a deficit between total liabilities and total equity on paper, which complicates any residual distribution scenario.

A concrete, past financial event impacting this group was the $\text{\$3M}$ Shareholder Settlement, where the claim deadline was set for January 13, 2025. For those who filed, the estimated average recovery, assuming a $\text{25\%}$ participation rate, was around $\text{\$0.08}$ per share. The company previously noted in its 2022 filings that if it ceased operations and liquidated assets, it was unlikely cash would be available for distributions to stockholders.

Here's a quick look at the key balance sheet components as of the latest available data:

Metric	Amount (USD Millions)	As of Date
Total Liabilities	$\text{7.56}$	November 2025
Total Current Liabilities	$\text{4.28}$	November 2025
Total Equity	$\text{6.44}$	November 2025

For Creditors: Orderly and legal resolution of all outstanding financial obligations

For creditors, the value proposition is tied directly to the company's ability to service its obligations, particularly the current ones, through its available assets. The focus here is on the Total Liabilities figure of $\text{7.56}$ million USD as of November 2025.

The immediate concern for creditors involves the current obligations, which stood at $\text{4.28}$ million USD in current liabilities in November 2025. This is the amount that needs to be addressed first in any wind-down or restructuring scenario.

The company has taken steps to conserve cash, including expected annual savings of approximately $\text{\$4.6}$ million from streamlining operations. This cash conservation effort directly supports the ability to meet financial obligations, which is the primary value for creditors.

The resolution process is framed by these key financial realities:

• Total Liabilities stood at $\text{7.56}$ million USD as of November 2025.
• Total Current Liabilities were $\text{4.28}$ million USD in November 2025.
• The company is focused on cash conservation measures.

For Regulators: Compliance with all final legal and dissolution reporting requirements

The value proposition for regulators, like the Securities and Exchange Commission (SEC), is the commitment to a clean, legal exit from active public reporting. Ampio Pharmaceuticals, Inc. announced in March 2024 its determination to voluntarily delist its common stock from the NYSE American and pursue SEC deregistration.

This action directly addresses the regulatory burden. The plan involved filing a Form 15 with the SEC around April 15, 2024, to suspend reporting obligations under the Exchange Act, which includes Forms 10-K, 10-Q, and 8-K.

The key compliance points are:

• Intent to file Form 15 to suspend reporting obligations.
• The process aims to terminate other SEC filing requirements upon the effectiveness of deregistration.
• The company is navigating the resolution of pending legal proceedings.

Finance: draft 13-week cash view by Friday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Customer Relationships

You're looking at the customer relationships for Ampio Pharmaceuticals, Inc. as of late 2025, and honestly, it's less about selling a product and more about managing the final administrative wind-down following the dissolution approved in August 2024. The relationship with the former customer base-the stockholders-is now almost entirely transactional and governed by legal necessity.

Transactional communication with shareholders via the transfer agent

The primary point of contact for former stockholders regarding their equity is through the designated transfer agent, Equiniti. This communication is strictly transactional, dealing with the mechanics of any final cash distribution, which is contingent on settling all legal obligations and receiving approval from the Delaware Chancery Court. As of November 28, 2025, the remaining market capitalization stood at a nominal $5.9K, which gives you a sense of the scale of assets being managed through this final process. You should direct any specific questions about stockholdings to your broker or Equiniti, as the company itself is dissolved.

• Address stockholding questions to Equiniti.
• Cash distribution timing is subject to court approval.
• The company discontinued development of Ampion in February 2024.

Formal legal and administrative correspondence with legal counsel and courts

This is where the bulk of the remaining activity lies. The company's focus is on finalizing the settlement of past litigation. You'll recall the securities fraud class action and the consolidated derivative actions. A settlement in principle was reported in January 2024, and the Court preliminarily approved the securities settlement on September 24, 2024. This proposed settlement created a $3,000,000 Settlement Fund, plus interest, less fees and expenses. The deadline for stockholders to object or exclude themselves from this settlement was January 29, 2025. All ongoing administrative correspondence is channeled through legal counsel to the Delaware Chancery Court to secure the final order necessary to distribute any remaining cash after these obligations are met. The company voluntarily delisted and began SEC deregistration in April 2024, meaning formal SEC reporting relationships have been terminated.

Here's a quick look at the key administrative touchpoints governing the final phase:

Administrative Entity	Key Action/Status	Relevant Date/Amount
Delaware Chancery Court	Approves final cash distribution plan	Post-settlement finalization
Securities Class Action Settlement Fund	Proposed principal amount	$3,000,000
Securities Settlement Opt-Out/Object Deadline	Final administrative cutoff for class members	January 29, 2025
Transfer Agent	Handles shareholder account inquiries	Equiniti

Minimal, necessary contact with vendors for contract termination

With the dissolution effective August 16, 2024, and the discontinuation of the OA-201 program in February 2024, the need for ongoing vendor relationships has dropped to near zero. Any remaining contact is purely administrative, focused on finalizing any outstanding termination clauses or settling final invoices related to the wind-down of operations and the cessation of clinical development activities. The relationship is defined by closure, not ongoing service provision. The company's operational footprint is minimal, reflecting the focus on asset liquidation and legal finalization rather than business continuity.

• OA-201 program terminated in February 2024.
• Vendor contact limited to contract finalization.
• Reporting obligations under the Exchange Act terminated in April 2024.

Finance: draft 13-week cash view by Friday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Channels

You're looking at the channels Ampio Pharmaceuticals, Inc. uses to communicate with stakeholders and facilitate post-operational activities as of late 2025, given the company's wind-down status following the termination of its primary development program.

Corporate website for dissolution updates and official notices

The corporate website remains a primary, albeit static, channel for official notices related to the company's ongoing wind-down and the suspension of its SEC reporting obligations. Key contact points listed for inquiries include:

• Chief Executive Officer email: mmartino@ampiopharma.com
• General and Proxy inquiries email: info@ampiopharma.com

The company completed its voluntary delisting from the NYSE American on or about April 14, 2024, and intended to suspend its reporting obligations by filing Form 15 around April 15, 2024.

Legal administrators for processing shareholder settlement claims

The processing of past shareholder claims is managed through a court-appointed administrator, a critical channel for former investors seeking recovery from the settled litigation. The proposed settlement amount is $3,000,000.

Here are the key details regarding the settlement administration:

Settlement Administrator	Simpluris, Inc.
Total Settlement Fund	$3,000,000
Claim Submission Deadline	January 13, 2025
Final Approval Hearing Date	February 19, 2025
Claimant Purchase Period	December 29, 2020, through August 2, 2022
Estimated Average Recovery Per Share	Approximately $0.015 (post-deductions)

The distribution of the Net Settlement Fund to eligible Settlement Class Members is contingent upon the Court's final approval, which was sought in February 2025.

OTC Pink Market for common stock trading (following voluntary delisting in 2024)

Following the voluntary delisting from the NYSE American in 2024, Ampio Pharmaceuticals, Inc. common stock trades on the OTC Markets, specifically the OTC Pink Market, under the ticker AMPE. This is the current venue for any remaining public trading activity. The operational scale is minimal, reflecting the company's wind-down status.

Current trading metrics as of December 3, 2025, illustrate this:

Metric	Value as of Dec 3, 2025
Stock Price	0.0052 USD
Market Capitalization	$5.9 thousand
52-Week Range	0.0001 USD to 0.1643 USD
Earnings Per Share (TTM)	-10.66
Total Employees	6

The stock has shown extreme price compression, with the market cap at $5.9K as of November 28, 2025, compared to a historical high market cap of 34.12M since March 10, 2010. Trading volume is also thin, with an average daily volume of 1.32K shares.

Finance: review the cash position against the remaining administrative costs by next Tuesday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Customer Segments

You're looking at the final stages of a company's financial obligations, not a growth market. For Ampio Pharmaceuticals, Inc. (AMPE) as of late 2025, the customer segments are essentially the parties due a final distribution or settlement payment stemming from past corporate or legal actions, not product sales.

The primary focus is on resolving the securities litigation, which dictates the largest defined financial outflow. This means the 'customers' are claimants against the corporate estate or the legal entities managing that distribution.

Former shareholders of AMPE common stock seeking final distribution

This group consists of investors who acquired Ampio common stock during the defined class period and submitted a valid claim form by the deadline of January 13, 2025.

• Purchased or acquired AMPE common stock between December 29, 2020, and August 2, 2022.
• Eligible to share in the distribution of the Net Settlement Fund.
• The estimated average recovery per share, after deductions for fees and expenses, was approximately $0.015 per share.
• If 100% of eligible investors filed claims, the estimated average recovery was $0.02 per share before deductions.

Legal administrators and claimants involved in the $3 million settlement

This segment includes the court-appointed administrators and the legal counsel managing the distribution of the $3,000,000 Settlement Fund. Their role is to process claims and deduct their approved fees and expenses from the gross fund before the remainder goes to the shareholders.

Here's a quick math breakdown of the initial $3,000,000 fund allocation, which directly impacts the Net Settlement Fund available for claimants:

Component	Amount/Percentage	Reference Point
Total Settlement Fund	$3,000,000	Cash established for the settlement.
Attorneys' Fees	28% of the Settlement Fund	To be paid to Lead Counsel.
Lead Counsel Expenses	Up to $75,000	Plus accrued interest.
Lead Plaintiffs' Costs	Up to $5,000	For reasonable costs and expenses.

Remaining creditors and vendors with outstanding invoices

This segment represents entities that provided goods or services to Ampio Pharmaceuticals, Inc. and hold outstanding invoices. While the securities settlement is a defined financial event, the status and total amount owed to general creditors are not publicly detailed in the same manner as the class action settlement. Still, these parties are crucial stakeholders in any final corporate wind-down or asset distribution process post-litigation resolution.

• These parties are generally addressed through bankruptcy proceedings or direct liquidation agreements, which are separate from the securities class action.
• The company's financial reporting, such as the Amended Annual Report (10-k/a) filed as of November 25, 2025, would contain the latest figures on total liabilities, though specific vendor balances aren't itemized here.
• The priority of payment for these creditors relative to the settlement fund is a key financial consideration in the overall wind-down strategy.

Finance: draft 13-week cash view by Friday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Cost Structure

The Cost Structure for Ampio Pharmaceuticals, Inc. as of late 2025 reflects a significant shift towards wind-down activities following the voluntary delisting and intent to terminate SEC reporting obligations announced in early 2024.

The primary cost drivers are concentrated in final legal obligations, minimal essential overhead, and the execution of the deregistration process. Here is a breakdown of the relevant financial figures:

Cost Category	Financial Amount (USD)	Reference Period/Context
Legal and professional fees for dissolution and litigation defense	\$6,896,000	Professional Fees (2022 Annual)
Minimal remaining personnel costs for essential corporate functions	\$1,485,000	Salaries and benefits (2022 Annual)
Facility and office sublease costs, targeting annual savings	\$4,600,000	Targeted Annual Savings
Administrative costs for SEC deregistration and final reporting	No specific 2025 figure available	Post-Form 15 Filing Phase
Securities Settlement Fund (One-time Cost)	\$3,000,000	Settlement Fund (2024 Preliminary Approval)

You should note the following specific cost elements that feed into the overall structure:

• Legal and professional fees for dissolution and litigation defense, which historically included significant amounts for investigations and lawsuits, such as the \$4.4 million increase in professional fees noted in 2022 related to legal costs.
• Minimal remaining personnel costs for essential corporate functions, which were \$1,141,000 for salaries and benefits in 2021, increasing to \$1,485,000 in 2022 before expected reductions for wind-down.
• Facility and office sublease costs, targeting annual savings of \$4.6 million, which aligns with the prior facility lease expiring in September 2024.
• Administrative costs for SEC deregistration and final reporting, which follow the filing of Form 15 to suspend obligations like Forms 10-K, 10-Q, and 8-K.

The litigation component includes the one-time cost associated with the securities settlement:

• The proposed Settlement Fund was set at \$3,000,000 plus interest.
• Attorneys for Lead Plaintiffs sought 28% of the Settlement Fund plus up to \$75,000 for expenses.
• Lead Plaintiffs sought an award of up to \$5,000 for reasonable costs and expenses.

General and Administrative expenses in the last reported full year totaled \$11,466,000, a significant increase from the \$8,671,000 reported the prior year.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Revenue Streams

You're looking at the revenue streams for Ampio Pharmaceuticals, Inc. (AMPE) as of late 2025. Given the company's status as a pre-revenue stage biopharmaceutical entity, the revenue profile is heavily weighted toward non-operating sources, which is typical for a firm focused on preclinical development like their AR-300 program. Honestly, the core business activity isn't selling drugs yet; it's about managing capital until a major clinical or strategic event occurs.

The structure of revenue streams reflects a company in a holding or transition phase, relying on its existing financial assets rather than product sales. To be fair, this is a common, albeit precarious, position for many development-stage biotechs.

Interest income generated from remaining cash reserves is a key component. Based on the latest available income statement data for the nine months ended September 30, 2023, the company recognized $0.1 million in interest income, which was partially offset by a derivative gain of $1.2 million for that period. This income is directly tied to the size and management of their liquid assets.

Potential proceeds from the sale or licensing of residual intellectual property (IP) remain a theoretical, high-impact stream. While Ampio Pharmaceuticals, Inc. has historically held a portfolio of patents, including those related to their discontinued Ampion product and the ongoing AR-300 development, there are no publicly reported figures for 2025 regarding any specific licensing agreements or asset sales. The IP strategy remains a potential lever for future capital events, but it hasn't translated into realized revenue for the current period.

The required figure for operating revenue from drug sales or development activities in 2025 is $0. This aligns with the company's historical reporting as a pre-revenue stage entity focused on preclinical work, as confirmed by their 2022 filings.

Here's a quick look at the latest concrete financial figures we have to anchor these revenue expectations:

Financial Metric	Latest Reported Value (USD)	Reporting Date/Period End
Operating Revenue (Required for 2025)	$0	Fiscal Year 2025
Interest Income (Latest Reported)	$0.1 million	Nine Months Ended September 30, 2023
Cash and Equivalents (Latest Reported Balance)	$5.375 million	September 30, 2023
Cash and Cash Equivalents (Prior Year End)	$12.7 million	December 31, 2022

The reliance on interest income is a function of the cash balance. You'll want to track the cash flow statement closely, as the burn rate dictates how long this interest income stream can persist without new financing or a strategic transaction. The cash balance as of September 30, 2023, was $5.375 million, adjusted for a 20-to-1 reverse stock split effected in September 2023.

The potential for IP monetization is a binary event-it's either zero or a significant, non-recurring cash infusion. The company's focus on AR-300 preclinical data is the primary driver for any future value realization, which could lead to licensing deals, but that isn't a predictable revenue stream right now.

For your planning, keep an eye on these key areas that feed into the revenue picture:

• Cash burn rate from operating expenses.
• Progress and data readouts for the AR-300 program.
• Any public statements regarding strategic alternatives, including potential M&A or asset divestitures.

Finance: draft 13-week cash view by Friday.